Abstract
Background: The risk of tamoxifen related endometrial neoplasm has been confirmed by multiple studies. Case: The case of a 65-year-old multiparous postmenopausal woman who received tamoxifen 20 mg daily for 4 years after the treatment of breast cancer is presented. Four years after initiation of tamoxifen treatment, the patient developed a malignant mixed mesodermal tumor (MMMT) of the uterus. She was treated surgically with adjuvant radiotherapy. Conclusions: The benefits of adjuvant tamoxifen therapy outweigh the increased risk of uterine cancer, but the risk of uterine cancer continues for years after tamoxifen is discontinued. (J GYNECOL SURG 28:418)
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
